Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) presents a significant unmet need.
• Patient-reported outcomes (PROs) are crucial in evaluating treatment efficacy and patient experience.

Purpose of the Study:

• To assess the impact of odronextamab on PROs in patients with r/r DLBCL.
• To evaluate the clinical meaningfulness of observed PRO improvements.

Main Methods:

• The ELM-2 study (NCT03888105) included 141 patients with r/r DLBCL.
• Patients received odronextamab 160 mg weekly after step-up dosing.
• PROs were measured using FACT-Lym, FACT-G, TOI, EORTC QLQ-C30, and EQ-5D-3L.

Main Results:

• Odronextamab significantly improved FACT-Lym Lymphoma Subscale (LymS), FACT-General (FACT-G), Trial Outcome Index (TOI), and Total Score.
• Improvements were also observed in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) and EQ-5D-3L visual analog scale (VAS).
• Improvements in FACT LymS were clinically meaningful, with most patients reporting meaningful improvement or maintenance.

Conclusions:

• Odronextamab monotherapy demonstrated significant improvements in PROs for patients with r/r DLBCL.
• These PRO improvements support the feasibility of odronextamab as a potential treatment option.
• Odronextamab offers a promising therapeutic avenue for patients with relapsed/refractory disease.